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The vascular endothelial growth factor (VEGF), a homodimeric
glycoprotein of relative molecular mass 45 000, has been recently
identified as a vascular permeability factor, and as an endothelial
cell-specific mitogenic factor in vivo. By alternating splicing of
mRNA, four different isoforms with 121, 165, 189 and 206 amino
acids may be identified (Tischer et al, 1991; Houck et al, 1991).
These isoforms have different bioavailability, owing to their
different heparin-binding activity: VEGF-121 fails to bind heparin
and is secreted as a freely soluble protein. VEGF-165 is a basic,
heparin-binding protein and it is also secreted, but to a lesser
degree than the VEGF-121 isoform. The longer isoforms have a
greater affinity to heparin and are stably incorporated in the extra-
cellular matrix.
Several studies have shown that VEGF mRNA is expressed in a
variety of human tumours including renal (Brown et al, 1993),
mammary (Brown et al, 1995; Toi et al, 1996; Yoshiji et al, 1996),
colonic (Takahashi et al, 1995), œsophageal (Inoue et al, 1997),
gastric (Maeda et al, 1996), hepatocellular (Suzuki et al, 1996),
ovarian (Abu-Jawdeh et al, 1996) and lung (Mattern et al, 1995,
1996; Otha et al, 1996; Volm et al, 1996a, 1996b) carcinomas.
Because the VEGF expression has been shown to be strictly
related to neovascularization and poor prognosis in different types
of human cancers (Mattern et al, 1995; Takahashi et al, 1995;
Volm et al, 1996a), it may be useful to analyse the VEGF mRNA
expression with particular regard to its different isoforms. The role
of VEGF in the behaviour of human cancer could be particularly
interesting because it might represent an excellent target for the
development of new anti-tumour strategies, based on the inhibi-
tion of tumour angiogenesis (Martiny-Baron et al, 1995). In this
respect, non-small-cell lung carcinoma, in which neoangiogenesis
seems to be an important adjunctive prognostic indicator
(Macchiarini et al, 1992; Fontanini et al, 1995; Angeletti et al,
1996; Harpole et al, 1996) providing useful information on new
therapeutic approaches, may represent an interesting human model
to investigate the influence of VEGF in its development and
progression.
In this study, we analysed the VEGF mRNA expression by
reverse transcription polymerase chain reaction (RT-PCR) and in
situ hybridization to better define the role of this angiogenic factor
in the behaviour of non-small-cell lung cancer (NSCLC).
MATERIALS AND METHODS
Tissue samples
Non-small-cell lung cancer tissues obtained from 42 patients who
received surgery at the S. Chiara Hospital of Pisa University, Italy,
between 1991 and 1994 were frozen and stored at –80°C. Eighteen
fragments from surrounding normal tissues were also analysed.
There were 38 men and four women (mean age 62.4, range
42–77). Median follow-up was 39.5 months (range 22–59). The
patients presented no detectable metastases in distant organs at the
time of surgery. Tumour samples were formalin-fixed and
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Pathology, via Roma, 57, 56126 Pisa, Italyparaffin-embedded for histological examination and immunohisto-
chemical analysis of the microvascular endothelium. Tumour frag-
ments were analysed according to the WHO histological
classification (World Health Organization, 1982) and the guide-
lines of the American Joint Committee for Cancer Staging
(American Joint Committee on Cancer, 1992) with regard to
pathological studies.
Microvessel detection and counting
In all cases, the number of microvessels in the tumours was deter-
mined after highlighting vessel endothelium with a monoclonal
antibody (QB-END Novocastra Laboratories, Newcastle, UK)
directed against the CD34 antigen. A single microvessel was
defined as any brown, immunostained endothelial cell separated
from adjacent microvessels, tumour cells and connective tissue
elements. In each sample, the three most intense regions of
neovascularization under low microscopic power (´ 10 objective
lens and ´ 10 ocular lens) were identified. A ´ 250 field (´ 25
objective lens and ´ 10 ocular lens; 0.74 mm2 per field) in each of
these three areas was then counted, and the average count of the
three fields was recorded. Large vessels with thick, muscular walls
were excluded from the counts. The presence of a lumen was not
required to identify a microvessel.
RT-PCR analysis
Total RNA was extracted from frozen lung tissues using a RNA
extraction reagent, Ultraspec RNA, according to the standard
acid–guanidium–phenol–chloroform method. Five micrograms of
total RNA were reverse transcribed at 42°C for 60 min in a total
20-ml reaction volume using a 1st-Strand cDNA synthesis kit
(Clontech Laboratories, Palo Alto, CA, USA). cDNA was incu-
bated at 95°C for 5 min to inactivate the reverse transcriptase, and
served as template DNA for 30 rounds of amplification using the
Gene Amp PCR System 2400 (Perkin-Elmer Applied Biosystems,
CA, USA). PCR was performed in a standard 50-ml reaction
mixture consisting of 10 mM Tris-HCl, 50 mM potassium chloride,
1.5 mM magnesium chloride (pH 8.3), 0.2 mM dNTPs, 50 pmol of
each sense and antisense primer and 2.5 U of Amplitaq DNA poly-
merase (Perkin-Elmer Applied Biosystems). Amplification was
performed for 30 sec at 94°C, 1 min at 55°C and 1 min at 72°C.
Finally, an additional extension step was carried out for 2 min. As
negative control, the DNA template was omitted in the reaction.
The amplification products were separated on 1.5% agarose gels
and visualized by ethidium bromide staining. PCR primers for
VEGF cDNA were as follows: forward primer, 5¢-TGGATCCAT-
GAACTTTCTGCTGTC-3¢; reverse primer, 5¢-TCACCGCCTTG-
GCTTGTCACAT-3¢ according to the VEGF gene structure. Three
kinds of PCR product of 656 bp, 584 bp and 452 bp encoding
VEGF isoforms VEGF –189, VEGF –165 and VEGF –121,
respectively, were obtained. For GAPDH, the forward primer was
5¢-CGATGCTGGCGCTGAGTAC-3¢ and the reverse primer was
5¢-CGTTCAGCTCAGGGATGACC-3¢ (Wizigmann-Voos et al,
1995). The presence of a single 412-bp band amplified with
primers specific for GAPDH with the same cDNAs was used as
internal control under identical conditions.
In situ hybridization
In situ hybridization was performed in 24 out of 42 cases using
a 40-bp 3¢-biotin-labelled, single-stranded synthetic probe
(Oncogene Science, Manhasset, NY, USA) to identify the VEGF
mRNA sequence. Briefly, formalin-fixed and paraffin-embedded
tumour samples were cut, mounted on APES-coated slides and
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Table 1 Univariate analysis of the association between clinicopathological
parameters and overall survival in 42 cases of NSCLC
Patient and tumour No of cases Two-sided P-value*
characteristics
Sex
Men 37 0.4
Women 5
Age
≤ 64 24 0.6
> 64 18
Histology
Squamous 21
Adenocarcinoma 15 0.2
Anaplastic large cell 3
Bronchioloalveolar 3
Tumour size
T1 10
T2 27 0.04
T3 5
Node status
N0 25
N1 6 0.02
N2 11
Stage
S1 24
S2 5 0.03
S3 13
*Cox’s F-model.
A
B
VEGF
GAPDH 412 bp
452 bp
584 bp
656 bp
13 4 2
Figure 1 (A) Identification by RT-PCR of VEGF isoforms expressed in
human lung carcinomas. Expected VEGF amplification products of 452, 584
and 656 bp correspond to VEGF isoforms VEGF-121, VEGF-165 and VEGF-
189 respectively. (B) A single 412-bp band amplified with primers specific for
GAPDH with the same cDNAs under identical conditions. Lanes 1, 2, 3, 4:
four NSCLC samplesbaked at 37°C overnight. Slides were dewaxed with xylene and
rehydrated through graded alcohols at room temperature. After
washing in 0.1% diethylpyrocarbonate (DEPC)-treated water, the
slides were soaked in 2 ´ standard saline citrate (SSC) (0.3 M
sodium chloride, 30 mM sodium citrate) at 60°C for 10 min
followed by digestion with proteinase K (20 mg ml–1 in 0.05 M Tris,
pH 7.6) at 37°C for 1 h. Sections were then fixed in 0.4%
paraformaldehyde/phosphate-buffered saline (PBS) at 4°C for 20
min. After brief washing in DEPC-treated water and incubation in
prehybridization buffer (37°C for 1 h), a hybridization solution
containing labelled probe (0.2 mg ml–1) was applied to the sections,
coverslips were added and the slides were incubated in a moist
chamber overnight at 37°C. After hybridization with antisense
probe, the coverslips were removed and the slides were washed
sequentially in 4 ´ SSC (0.6 M sodium chloride, 60 mM sodium
citrate) containing 30% formamide, 2 ´ SSC at 37°C, and 0.2 ´
SSC (30 mM sodium chloride, 3 mM sodium citrate) at room
temperature. After immersion in 1 ´ modified Tris-buffered saline
(TBS) Tween 20 [50 mM Tris (pH 7.6), 150 mM sodium chloride
and 0.5% Tween 20], slides were incubated with streptavidin–HRP
(horseradish peroxidase) for 30 min at 37°C in a humid chamber; a
signal amplification technique was performed by incubation with
biotinylated-tyramide for 10 min at room temperature. The
colouring reaction was performed by aminoethylcarbazole (AEC).
The slides were rinsed in water, counterstained with haematoxylin,
and mounted with aqueous mounting. Two controls were used to
check the specificity of the hybridization signal: a RNAAse
pretreatment of the tissue sections and a substitution of the anti-
sense probe with a biotin-labelled random probe. This random
probe was a 40-bp single-stranded synthetic oligonucleotide with
randomized sequence, except for the 3¢ end deoxyadenosine base,
and was used under the same stringency conditions.
Statistical analysis
All statistical analyses were carried out by the Statistica software
system. Survival curves were obtained by the Kaplan–Meier
method, and survival rate was assessed by Cox’s F-model. The
relationship between VEGF expression and clinicopathological
characteristics was analysed by the contingency tables.
RESULTS
Patients and tumour characteristics
The most common histological type was squamous cell carcinoma
(50%) followed by adenocarcinoma (35.7%), large-cell anaplastic
carcinoma (7.15%) and bronchioloalveolar carcinoma (7.15%).
With respect to tumour size, ten (23.8%) tumours were classified as
T1, 27 (64.3%) were classified as T2 and five (11.9%) were classi-
fied as T3. Six (14.3%) cancers showed metastatic involvement of
the hilar lymph nodes (N1), whereas mediastinal lymph nodes (N2)
were involved in 11 (26.1%) cancers. No metastatic involvement
(N0) was present in 25 (59.5%) patients. Most cases were classified
as stage I (24; 57.1%), five (11.9%) were classified as stage II and
13 (31%) were classified as stage III. Nineteen (45.2) patients
relapsed during follow-up. At the time of analysis, 28 (66.6%)
patients were alive, whereas 14 (33.4%) patients were dead.
Clinicopathological characteristics and survival
Among the clinicopathological parameters, greater tumour size
(test for trend, two-sided P = 0.04), metastatic nodal involvement
(test for trend, two-sided P = 0.02) and advanced stage (test for
trend, two-sided P = 0.03) were significantly associated with a
worse overall survival (Table 1).
RT-PCR analysis of VEGF mRNA in normal and NSCLC
tissues
RT-PCR analysis revealed that VEGF mRNA was expressed in the
lung tumours of 33 out of 42 patients examined (78.6%). Three kinds
of amplified cDNAs (VEGF-121, VEGF-165, VEGF-189) were
detected. Amplification products corresponding to VEGF 206 were
undetectable. Thirteen out of 42 (31%) cases expressed the VEGF-
189 isoform; 24 out of 42 (57.1%) expressed the VEGF-165 isoform
and 32 out of 42 (76.1%) showed the VEGF-121 splice. Nine out of
33 (27.3%) expressed the VEGF-121 isoform alone; in 23 out of 33
(69.7%) cases, the two secretory forms (VEGF-121 and VEGF-165)
were concomitantly detected. Of the samples, 39.4% showed all three
isoforms, whereas only one case (3.03%) was positive for VEGF-165
alone. Figure 1 shows the results of the electrophoretic analysis of
PCR products in representative cases. In 18 cases, fragments of
surrounding normal lung tissue were also examined. Seventeen out of
18 (94.4%) cases showed VEGF mRNA positivity with preponderant
expression of the 121 and 165 isoforms. One negative case showed
no VEGF mRNA expression, even in the tumoral part. Figure 2
shows the results of the electophoretic analysis of PCR products for
VEGF in three representative parenchyma/tumour (P/T) couples.
In situ hybridization
VEGF antisense probes were used to perform in situ hybridization in
24 of the 42 cases analysed. As shown in Figure 3, the VEGF
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Figure 2 (A) The results of the electrophoretic analysis of PCR products for
VEGF in three representative parenchyma/tumour (P/T) couples: in the first
couple, both normal lung tissue and tumoral part were negative for the VEGF
expression; in the second couple, the VEGF signal was revealed in both
tissues although with different patterns of VEGF isoforms; in the third couple,
only the surrounding normal lung tissue showed VEGF expression. Lane M:
100-b-p ladder (Pharmacia Biotech). Lane C: negative control, with no cDNA
added to PCR mixture. (B) a single 412-bp band amplified with primers
specific for GAPDH with the same cDNAs under identical conditions
A
B
VEGF
GAPDH 412 bp
452 bp
584 bp
656 bp
PP P TT T C MmRNA expression was widely detected in the cytoplasm of tumour
cells in 75% of the cases (Figure 3A). In 21 of the 24 cases analysed,
surrounding lung tissue was concomitantly present and the VEGF
mRNA expression was revealed in the cytoplasm of hyperplastic
alveolar cells (Figure 3B) and/or normal columnar cells lining
submucosal glands (Figure 3C) in 47.6% of cases; moreover,
several inflammatory cells expressed VEGF transcript (Figure 3D).
No VEGF mRNA expression was detected in the endothelial cells.
Figure 4A and B shows in situ hybridization with both antisense and
random probes in one case of lung adenocarcinoma.
VEGF mRNA expression and clinicopathological
parameters
The VEGF mRNA expression was compared with the clinical and
histological features of the tumours. The comparison between the
different isoforms of VEGF and clinicopathological characteristics
of the tumours is shown in Table 2. No association was found
between VEGF transcript and age or sex of the patients, nor with
histology and size of the tumour. A significant association was
present between the VEGF-121 isoform and nodal status. In fact,
of the 17 tumours with metastatic nodal involvement at the
moment of resection, 16 were positive for the VEGF-121 form
(P= 0.02, chi-squared test).
VEGF mRNA expression and survival
The relation between the VEGF mRNA expression and survival
was also investigated. Patients with VEGF-mRNA-negative
tumours showed better disease-free and overall survival (P= 0.03,
P= 0.02) than those patients with VEGF-mRNA-positive tumours
(Figure 5A and B). The prognostic impact of the different isoforms
was also analysed. The VEGF-mRNA-165 expression signifi-
cantly affected overall survival (P= 0.01) (Figure 6), in contrast to
the other two isoforms.
VEGF mRNA expression and microvessel density
To examine a possible relationship between VEGF mRNA expres-
sion and microvessel density, the data were analysed by the T-test
for independent samples. Mean vessel count (±s.d.) was higher in
VEGF-mRNA-positive tumours (29.8 ±23.5) than in VEGF-
mRNA-negative tumours (23 ±11.4), although this difference was
not statistically significant (P= 0.49). Similar results were obtained
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A
C
B
D
Figure 3Non-radioactive in situ hybridization in a sample of non-small-cell lung cancer (A). Normal alveolar cells (B), epithelium lining sub-mucosal glands
(C) (arrows) and inflammatory cells (D) in a sample of normal lung tissue expressing VEGF mRNA. The sections were hybridized with antisense VEGF probewhen the association between vascular density and the three
different isoforms of VEGF mRNA was analysed (data not shown).
DISCUSSION
VEGF has been identified recently as a secreted endothelial cell-
specific mitogen able to stimulate angiogenesis in vivo (Ferrara,
1995; Shibuya et al, 1995). Four different isoforms (VEGF-121,
VEGF-165, VEGF-189, VEGF-206) have been described in
tumours as alternative splicing of a single gene (Tiesher et al,
1991). Transcripts encoding the three shorter forms, 121, 165 and
189, have been detected in the majority of tumour cells expressing
the VEGF gene. VEGF-121 and VEGF-165 isoforms are effi-
ciently secreted and mostly stimulate the mitogenic properties of
endothelial cells. On the contrary, the longer isoforms (VEGF-189
and VEGF-206) are generally cell-associated and linked to
vascular permeability (Ferrara, 1995). However, the significance
of the various isoforms has not been completely explained.
According to the different availability and affinity with their recep-
tors, they could be differently involved in the development of
tumoral angiogenesis.
VEGF expression in NSCLC
Several studies have analysed the VEGF expression in human
cancers such as mammary (Brown et al, 1995; Toi et al, 1996;
Yoshiji et al, 1996), urinary (Brown et al, 1993), gastric (Maeda et
al, 1996), colonic (Takahashi et al, 1995), ovarian (Abu-Jawdeh et
al, 1996) hepatocellular (Suzuki et al, 1996) and lung (Mattern et
al, 1995, 1996; Otha et al, 1996; Volm et al, 1996a, 1996b) carci-
nomas. In these studies, mRNA analysis showed a predominant
expression of the VEGF secretory forms 121 and 165. According
VEGF expression in lung cancer 367
British Journal of Cancer (1999) 79(2), 363–369 © Cancer Research Campaign 1999
A
B
Figure 4 Non-radioactive in situ hybridization with both antisense (A,
arrows) and random probes (B) in one case of lung adenocarcinoma
Table 2 VEGF mRNA expression according to clinicopathological characteristics
Variables VEGF-189 P-value VEGF-165 P-value VEGF-121 P-value
Positive Negative Positive Negative Positive Negative
Age 61.4 ± 7 62.8 ± 8 NS 62.1 ± 9 62.8 ± 7 NS 61.7 ± 7 64.5 ± 8N S
(mean ± s.d.)
Sex
Men 11 26 21 16 28 9
NS NS NS
Women 2 3 3 2 4 1
Histology
Squamous 9 12 15 6 18 3
Adeno 4 11 8 7 10 5
NS NS NS
Anaplastic 0 3 1 2 3 0
Br/Al 0 3 0 3 1 2
T-status
T1 4 6 4 6 8 2
T2 7 20 NS 16 11 NS 19 8 NS
T3 2 3 4 1 5 0
N-Status
N0 7 18 12 13 16 9
NS NS 0.02
N1–2 6 11 12 5 16 1to these data, the results of our RT-PCR analysis revealed a similar
pattern of the VEGF expression. Moreover, in our study, the
VEGF expression was detected in almost all cases of the adjacent
non-neoplastic tissues. This agrees with the putative biological
role of VEGF in that it maintains the permeability of normal lung
tissues. The frequent expression of VEGF mRNA in non-
neoplastic samples found in our series may also be explained by
the presence of inflammatory changes, which are often detected
concomitantly with this type of neoplastic lesion. This is
confirmed by in situ hybridization results which showed a clear
expression of VEGF mRNA in the cytoplasm of tumour cells, and
even in normal and inflammatory elements as well as in the hyper-
plastic type II alveolar cells which are usually present in the
inflammatory response. As regards normal tissue, VEGF mRNA
positivity was predominantly found in the cytoplasm of alveolar
cells. Only a few cases of epithelial cells lining submucosal glan-
dulae showed VEGF expression. Thus, the VEGF expression
detected in squamous and adenocarcinomas (arising from
bronchial-lining epithelium) may actually be considered as strictly
related to the progression of NSCLC with likely prognostic impli-
cations; conversely, because two of the three cases of bronchi-
oloalveolar carcinoma were VEGF negative, we can suppose that
in the alveolar-arising tumours, such as the bronchioloalveolar
tumours, VEGF will have a different role. However, further
analyses by quantitative PCR will be necessary to confirm the
higher mRNA VEGF levels in tumour cells compared with normal
tissues. The different percentages of the VEGF cases expressing
VEGF in tumour samples by using RT-PCR and in situ hybridiza-
tion (ISH) (94.4% by PCR vs 75% by ISH) may probably be due
to the fact that with the RT-PCR method also very small amounts
of VEGF mRNA are detected, whereas with ISH greater amounts
of transcript are necessary for the signal to be observed.
VEGF expression and tumour progression
Several studies have analysed the relationship between VEGF
expression, clinicopathological features and survival (Takahashi et
al, 1995, 1996; Maeda et al, 1996; Toi et al, 1996; Volm et al,
1996a; Inoue et al, 1997) mostly by using immunohistochemical
techniques. In lung cancer, the VEGF mRNA expression has been
studied by Otha et al (1996) using RT-PCR assay. Interesting data
concerning the prognostic impact of VEGF have been reported.
However, their analysis included both non-small- and small-cell
lung carcinomas and only the contribution of the VEGF-121
isoform was investigated. In our study, we confirmed the data by
Otha et al (1996) about the prognostic impact of VEGF on overall
survival. However, our study provides further information about
the influence of VEGF on the behaviour of this type of cancer. In
fact, a significant association was noticed between the VEGF-165
isoform and survival, with no significant association between the
121 and 189 isoforms and survival when the latter were individu-
ally analysed. This suggests the possibility of a predominant role
of isoform 165 in the progression of this type of cancer. However,
the significant association we found between the VEGF-121
isoform and nodal metastatic involvement underlines the impor-
tance of VEGF soluble isoforms as markers of aggressiveness in
this tumour. Our recent analysis concerning the relation between
high-VEGF protein expression and poor prognosis in a series of
107 NSCLC (Fontanini et al, 1997) agrees with the data obtained
with our RT-PCR analysis. A polyclonal antibody directed against
the 121, 165 and 189 amino acid splice variants was used to recog-
nize the VEGF antigen. This suggests that the cytoplasmic antigen
detected in cancer cells could be that of the secretory isoforms as
confirmed by RT-PCR analysis, which shows a predominant
expression of 121 and 165 isoforms. Moreover, in the present
study, the soluble isoforms are those related to poor prognosis and
metastasis, confirming the data of our previous study using the
immunohistochemical approach. However, these preliminary data
need further investigations in a larger and prospective series of
patients to better understand the real role of the soluble isoforms in
the outcome of NSCLC, and before considering the expression of
the VEGF as a prognostic parameter in this type of cancer.
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Figure 5 Disease-free (A) and overall survival (B) curves for 42 patients
with non-small-cell lung cancer. The Kaplan–Meier method was used to
estimate disease-free and overall survival, and the Cox’s F-test was used to
compare the curves. Disease-free and overall survival were affected by
VEGF mRNA expression which was stratified in two groups: nine cases
negative and 33 cases positive
Figure 6 Overall survival curve in patients with non-small-cell lung cancer
according to VEGF-mRNA-165 isoform. The Kaplan–Meier method was used
to estimate overall survival, and the Cox’s F-test was used to compare the
curves. Overall survival was affected by VEGF-mRNA-165 isoform
expression which was stratified in two groups: 18 cases negative and 24
cases positive
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To investigate the influence of VEGF as a regulatory factor of
tumour angiogenesis, we analysed the relationship between this
factor and microvessel count of the tumours. Although the mean
microvessel count was higher in VEGF-positive compared with
VEGF-negative tumours, no significant statistical difference was
found. However, it is evident that the vascular phenotype in any
one tumour is the result of a larger number of factors influencing
angiogenesis; this process is driven by a complex array of soluble
mediators, matrix molecules and accessory cells that function so as
to fine tune and co-ordinate the response in both time and space.
This prompts us to further analyse a spectrum of both stimulating
and inhibiting angiogenic factors to better explain this process
with particular attention to NSCLC.
Although many questions remain to be solved, the close associ-
ation we found between VEGF mRNA expression and survival in
NSCLC underlines the importance of the evaluation of this angio-
genic factor in the biological assessment of this type of cancer. The
analysis of this factor is potentially important to evaluate the
angiogenic activity of tumours in order to develop new therapeutic
strategies directed against biological targets.
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